Microcap Ledger

Tickers · $MGNX

Macrogenics Inc $MGNX

By Microcap Ledger desk · CIK 0001125345

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
Nasdaq Global Select Market
Sector
Pharmaceutical Preparations
Headquarters
Rockville, MD
Fiscal year end
December 31
Shares outstanding
63,700,187 [10-Q 2026-08-14]
as of 2026-08-08

Sources: [10-K 2026-03-09]

What the company doesAI summary of filing

MacroGenics is a clinical-stage biopharmaceutical company that develops antibody-based therapeutics for cancer treatment using proprietary technology platforms including ADCs (antibody-drug conjugates) and multi-specific antibodies (DART and TRIDENT molecules). The company generates revenue from three FDA-approved marketed products (TZIELD, ZYNYZ, and MARGENZA) for which it retains economic rights, collaboration agreements that have provided over $1.6 billion in non-dilutive funding since inception, and contract development and manufacturing services provided through its commercial-scale cGMP facility in Maryland. MacroGenics is advancing three wholly-owned product candidates in clinical development (lorigerlimab, MGC026, and MGC028) and has partnered programs with Gilead Sciences and others. [10-K 2026-03-09]

Segments: DART and TRIDENT multi-specific antibody platforms, Antibody-drug conjugate (ADC) platform, Contract development and manufacturing services, Marketed products with retained economic rights

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
6 months to Jun 2026$39.55M−$17.26M −$76.56M$113.91M[10-Q 2026-08-14]
FY ended Dec 2025$149.50M−$74.6K −$81.04M$57.22M[10-K 2026-03-09]
FY ended Dec 2024$149.96M−$67.0K −$68.37M$182.84M[10-K 2026-03-09]
Quarterly cash burn
−$38.28M
Cash runway Estimate
~8.9 months

Estimate: cash at the end of the period (6 months to Jun 2026) divided by the average monthly operating cash outflow over that period. Ignores any cash raised or spent since, and any financing.

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2024-11-0162,763,448[10-Q 2024-11-05]
2025-03-1463,090,323[10-K 2025-03-20]
2025-05-0963,090,323[10-Q 2025-05-13]
2025-08-0863,205,703[10-Q 2025-08-14]
2025-11-0763,258,532[10-Q 2025-11-12]
2026-03-0563,555,837[10-K 2026-03-09]
2026-05-0863,563,123[10-Q 2026-05-13]
2026-08-0863,700,187[10-Q 2026-08-14]
Shelf registration
S-3 filed 2023-11-06; declared effective 2023-11-15 [S-3 2023-11-06]

Listing status

Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
DateInsiderTypeSharesPriceFiling
2026-10-06Bonvini Ezioexercise8,000$2.60[4 2026-10-07]
2026-08-19Peters Jeffrey Stuartsell31,105$4.15[4 2026-08-20]
2026-08-17Bonvini Ezioexercise40,000$2.60[4 2026-08-18]
2026-05-18O'Brien Federica F.exercise3,750—[4 2026-05-20]
2026-05-18Jackson Scott Thomasexercise3,750—[4 2026-05-20]
2026-05-18Heiden William Kexercise3,750—[4 2026-05-20]
2026-05-18Siegel Jay Philipexercise3,750—[4 2026-05-20]
2026-05-18Liu Margaretexercise3,750—[4 2026-05-20]

Catalysts and calendar

Recent filings and releases
DateTypeTitle
2026-08-1410-QQuarterly report
2026-08-1413G/ABeneficial ownership report (5%+ holder)
2026-08-138-KResults of operations
2026-08-0313G/ABeneficial ownership report (5%+ holder)
2026-07-2913GBeneficial ownership report (5%+ holder)
2026-07-238-KOther events
2026-07-2013G/ABeneficial ownership report (5%+ holder)
2026-07-088-KDirector or officer change
2026-07-078-KAcquisition or disposition completed; Regulation FD disclosure
2026-06-0513GBeneficial ownership report (5%+ holder)
2026-05-208-KShareholder vote results
2026-05-1513G/ABeneficial ownership report (5%+ holder)

Facts as of . Small caps move fast; check the latest filings.